Jeffrey Ming

TL;DR: In patients with persistent, moderate-to-severe asthma and elevated eosinophil levels who used inhaled glucocorticoids and LABAs, dupilumab therapy, as compared with placebo, was associated with fewer asthma exacerbations when LABs and inhaled GLPAs were withdrawn, with improved lung function and reduced levels of Th2-associated inflammatory markers.

TL;DR: Patients treated with dupilumab had marked and rapid improvement in all the evaluated measures of atopic dermatitis disease activity, and side-effect profiles were not dose-limiting.

TL;DR: This is the first report showing rapid improvement of the AD molecular signature with targeted anti-IL-4 receptor α therapy, and data suggest that IL-4 and IL-13 drive a complex, TH2-centered inflammatory axis in patients with AD.

TL;DR: Dupilumab reduced circulating concentrations of total IgE and TARC, indicating blockade of IL‐4Rα–mediated signaling, and had a favorable safety profile across the wide range of doses administered, support the continued development and use of dupilumAB in treatment of type 2 diseases.